Evidence map›Paper›PMID 37160547›Full record

ReviewCurrent oncology reports2023

Cellular Therapy for Children with Central Nervous System Tumors: Mining and Mapping the Correlative Data.

Erin E Crotty, Ashley L Wilson, Tom Davidson, Sophia Tahiri, Juliane Gust, Andrea M Griesinger, Sujatha Venkataraman, Julie R Park, Sabine Mueller, Brian R Rood and 3 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 2 countries.

Erin E CrottyBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, M/S JMB-8, 1900 9thAvenue, Seattle, WA, 98101, USA.
Ashley L WilsonSeattle Children's Therapeutics, Seattle, WA, USA.
Tom DavidsonCancer and Blood Disease Institute, Keck School of Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.
Sophia TahiriBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, M/S JMB-8, 1900 9thAvenue, Seattle, WA, 98101, USA.
Juliane GustDivision of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, WA, USA.
Andrea M GriesingerMorgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, CO, USA.
Sujatha VenkataramanMorgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, CO, USA.
Julie R ParkBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, M/S JMB-8, 1900 9thAvenue, Seattle, WA, 98101, USA.
Sabine MuellerDepartment of Neurology, Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Brian R RoodCenter for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
Eugene I HwangCenter for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
Leo D WangDepartments of Pediatrics and ImmunoOncology, City of Hope, Duarte, CA, USA.
Nicholas A VitanzaBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, M/S JMB-8, 1900 9thAvenue, Seattle, WA, 98101, USA. nicholas.vitanza@seattlechildrens.org.ORCID 0000-0002-3966-4985
Seattle Children's Hospital · USCenter for Cancer and Blood Disorders · USMorgan Adams Foundation · USCity Of Hope National Medical Center · USSeattle University · USUniversity of California, San Francisco · USUniversity of Southern California · USUniversity of Washington · US

Funding

Prospective evaluation of barriers to patient referral and enrollment in emerging cellular therapy trials: determining methods and structure to improve equity in future trial designU01TR002487 · NCATS · SEATTLE CHILDREN'S HOSPITAL · PI PARK, JULIE R, RAMSEY, BONNIE W · 2018 to 2022
$7.2M
NCATS NIH HHS U01 TR002487
6 · The paper itself

Abstract

purpose of reviewCorrelative studies should leverage clinical trial frameworks to conduct biospecimen analyses that provide insight into the bioactivity of the intervention and facilitate iteration toward future trials that further improve patient outcomes. In pediatric cellular immunotherapy trials, correlative studies enable deeper understanding of T cell mobilization, durability of immune activation, patterns of toxicity, and early detection of treatment response. Here, we review the correlative science in adoptive cell therapy (ACT) for childhood central nervous system (CNS) tumors, with a focus on existing chimeric antigen receptor (CAR) and T cell receptor (TCR)-expressing T cell therapies. RECENT

findingsWe highlight long-standing and more recently understood challenges for effective alignment of correlative data and offer practical considerations for current and future approaches to multi-omic analysis of serial tumor, serum, and cerebrospinal fluid (CSF) biospecimens. We highlight the preliminary success in collecting serial cytokine and proteomics from patients with CNS tumors on ACT clinical trials.

Indexed as

Central Nervous System NeoplasmsReceptors, Chimeric AntigenChildHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-CellReceptors, Chimeric AntigenAdoptive cellular therapyBiomarkersCorrelative studiesImmunotherapyPediatric CNS tumors

Identifiers

PMID37160547
PMCPMC10326126
OpenAlexW4376121608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.